Investigation of blood glucose levels in the perioperative period of bariatric/metabolic surgery using continuous glucose monitoring
Not Applicable
Recruiting
- Conditions
- Endocrine, nutritional and metabolic diseases
- Registration Number
- KCT0005240
- Lead Sponsor
- Seoul National University Bundang Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
(1) Aged over 19 year old men and women
(2) Type 2 diabetes
(3) BMI = 30.0 kg/m2
(4) BMI = 27.5 kg/m2 and poor glycemic control (HbA1c over 7.0) under standard medical care
(5) Provided written informed consent
Exclusion Criteria
(1) Prior bariatric/metabolic surgery
(2) Acute or chronic skin diseases which make hard to apply CGMS
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The mean difference in percentage time in range (70 - 180 mg/dL) before and after the surgery
- Secondary Outcome Measures
Name Time Method The mean difference in mean glucose level (total, daytime, and nighttime);The mean difference in glycemic variability (total, daytime, and nighttime);The mean difference in percentage time above range (>180 mg/dL and >250 mg/dL);The mean difference in percentage time below range (<70 mg/dL and <54 mg/dL; total, daytime, and nighttime) ;The mean difference in mean glucose level, glycemic variability, percentage time in range stratified by HbA1c level;Correlations between preoperative HbA1c and the difference in percentage time in range, and between age and the difference in HOMA-IR
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link continuous glucose monitoring to metabolic disease management post-bariatric surgery?
How does CGM-guided glucose control compare to standard-of-care in bariatric/metabolic surgery outcomes?
Which biomarkers correlate with perioperative glucose variability in metabolic disease patients undergoing bariatric surgery?
What adverse events are associated with CGM use in the perioperative period of bariatric surgery and how are they managed?
Are there combination approaches involving CGM and pharmacological agents for optimizing glucose control in metabolic disease patients post-bariatric surgery?